Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896970 | 0.87 | MAPK14 (0.59) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2978967 | 0.84 | MAPT (0.58) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7853049 | 0.82 | HDAC3 (0.49) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2979404 | 0.82 | SMN1; SMN2 (0.56) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2969766 | 0.81 | HDAC3 (0.51) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2970080 | 0.81 | MAPT (0.65) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL6400541 | 0.81 | PLAU (0.59) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL7854480 | 0.81 | RAB9A (0.50) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL28741190 | 0.81 | RAB9A (0.51) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2972292 | 0.78 | SMN1; SMN2 (0.52) | PLAUSMN1; SMN2NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| CN-1243724-C | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2006-03-01 | — | — | CN | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| CN-1350530-A | Amide derivatives | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
| CN-1330631-A | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2002-01-09 | — | — | CN | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | PLAU 2435/4885SMN1; SMN2 4288/4885NPC1 2786/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | PLAU 3125/4885SMN1; SMN2 2166/4885NPC1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.